Oramed Pharmaceuticals Issues Shareholder Update

NEW YORK , Feb. 9, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.  In addition, management and the Board of

Join our mailing list

Skip to content